8 results about "Tissue selectivity" patented technology

The invention discloses a nano-drug delivery system for treating myocardial fibrosis as well as a preparation method and application of the nano-drug delivery system, and belongs to the technical field of biological medicines. According to the system, ZIF-8 is taken as a core carrier, the loading efficiency of pirfenidone is improved through high specific surface area and adjustable aperture, PCM myocardial targeting peptide is covalently coupled on the surface, and the limitation of tissue selectivity is broken through. Through coordination complexation, pi-pi conjugate accumulation and electrostatic interaction synergy, stable drug loading and microenvironment response release are guaranteed; a one-pot method and a carbodiimide method are adopted to wrap PFD and modify PCM on the surface of ZIF-8 to form a nano-drug delivery system; according to the system, the fibrosis process is intervened through multiple mechanisms, the enrichment degree and the acting time of the medicine at the diseased region are improved, the prepared medicine integrates the carrier structure advantage and the targeting peptide function, efficient medicine carrying, precise delivery and controllable release are achieved, a new scheme is provided for myocardial fibrosis treatment, and the system has wide application prospects.

The invention provides an ablation device and a prostate tissue ablation system.The ablation tissue comprises a head electrode assembly, a needle electrode assembly and a handle assembly, the head electrode assembly comprises a head end main body and an outer tube which are connected with each other, the head end main body is arranged at the far end of the outer tube, a head electrode is arranged at the far end of the head end main body, and the needle electrode assembly is arranged on the outer tube. A needle electrode channel is arranged in the outer tube, the needle electrode assembly is contained in the needle electrode channel, the needle electrode assembly comprises at least one needle electrode, and the needle electrode assembly extends out of the side face of the ablation device based on operation on the handle assembly. According to the embodiment of the invention, the interventional operation of entering the urethra through a natural orifice and operating under a visual working condition and adopting an irreversible electroporation steep pulse electric field with tissue selectivity can be realized, so that the operation efficiency and the operation safety and effectiveness are greatly improved.

Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR / Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the triggerbinding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently. Disclosed herein are allosteric cgRNA mechanisms for both ON→OFF logic (conditional inactivation by an RNA trigger) and OFF→ON logic (conditional activation by an RNA trigger). Allosteric cgRNAs enable restriction of CRISPR / Cas function to a desired cell type, tissue, organ, or disease state. Allosteric cgRNAs provide a versatile platform for cell-selective and tissue-selective research tools, biotechnologies, diagnostics, and therapeutics.

This invention provides a medical repair membrane with an orthogonal crack-limiting structure and its preparation method. This invention relates to the field of biomedical materials technology. The medical repair membrane of this invention comprises at least two electrospun fiber layers, which intersect to form an orthogonal fiber structure. Layer B, facing tissue integration, adopts a coaxial core-shell structure. The shell layer contains biodegradable polymers and bioactive components, while the core layer is a biodegradable polymer. The structure of this invention effectively inhibits crack propagation and improves the structural stability of the material. Simultaneously, the core-shell structure enables controlled release of active components and tissue-selective induction, balancing mechanical properties and biocompatibility. The medical repair membrane is suitable for soft tissue defect repair, such as dura mater repair, fascia repair, pericardial repair, and hernia repair.

Disclosed in the present invention are a heteroaromatic amine compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound of the present invention has one or more of the following advantages: (1) excellent agonistic activity on 5-hydroxytryptamine 4 receptor; (2) good selective agonistic activity on 5-hydroxytryptamine 4 receptor; (3) capability of significantly reducing the risk of cardiotoxicity caused by hERG channel suppression; and (4) excellent intestinal tissue selectivity and low system exposure, which can reduce the safety risk of the circulatory system.

This invention discloses a photoproduce molecule targeting the PD-L1 immune checkpoint, its preparation method, and its application. Addressing the lack of tissue selectivity in existing PD-L1 small molecule inhibitors, this invention provides a photoproduce molecule as shown in general formula (I) or a pharmaceutically acceptable salt thereof, which covalently links a PD-L1 inhibitor to coumarin via a cleavable linker bond. This photoproduce can be rapidly activated (<10 min) under ultraviolet light, simultaneously releasing the fluorophore and the parent drug, achieving spatiotemporally controllable release of PD-L1 inhibitor activity. This invention also provides a synthesis method and its application in photoimmunotherapy.

The invention relates to heterozygous regulatory elements. Specifically, the present invention relates to hybrid transcriptional regulatory elements, in particular hybrid promoters, that drive gene expression, designed by fusion of at least two transcriptional regulatory elements having different tissue selectivity, for example two promoters that drive expression in different tissues in a tissue-selective manner.

A phosphor excitable by X-ray and blue-light emits light in the near-infrared (NIR-II, 1000-1700 nanometers) forms nanoparticles less than 200 nanometers diameter. The nanoparticles are tagged by coating with silica, then conjugating with polyethylene glycol (PEG) and tissue-selective compounds such as antibodies, nucleic acid chains, and other ligands. In embodiments, we administer the tagged nanoparticles to a subject, then localize the nanoparticles, and thus antigen-bearing tissues, by irradiating the subject with X-ray or other radiation beams while imaging near infrared light emitted from the subject. The nanoparticles are made by mixing 1-50 micron calcium oxide and germanium oxide powders with dilute nitric acid, adding chromium (III) nitrate at a ratio to germanium between 0.001 and 0.1, adding tartaric acid solution with molar ratio to metal ions between 1˜10, and adjusting pH to 0.1-4 with nitric acid, then later heating to form a sol, oven drying, and calcinating the sol.